{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T13:13:53Z","timestamp":1787750033368,"version":"build-2784847793"},"reference-count":45,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.cllc.2020.05.014","type":"journal-article","created":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T11:50:48Z","timestamp":1590148248000},"page":"e607-e621","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"title":["Pemetrexed-Based Chemotherapy Is Inferior to\u00a0Pemetrexed-Free Regimens in Thyroid Transcription Factor 1 (TTF-1)-Negative, EGFR\/ALK-Negative Lung Adenocarcinoma: A Propensity Score Matched Pairs Analysis"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7452-7129","authenticated-orcid":false,"given":"Nikolaj","family":"Frost","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamar","family":"Zhamurashvili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"von Laffert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick","family":"Klauschen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Ruwwe-Gl\u00f6senkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Raspe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Brunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Ochsenreither","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettina","family":"Temmesfeld-Wollbr\u00fcck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Suttorp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Groh\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9787-5633","authenticated-orcid":false,"given":"Martin","family":"Witzenrath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2020.05.014_bib1","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1002\/ijc.29670","article-title":"Cancer Incidence in five continents: inclusion criteria, highlights from Volume X and the global status of cancer registration","volume":"137","author":"Bray","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1016\/j.cllc.2020.05.014_bib2","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1016\/j.cllc.2020.05.014_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-319-24223-1_1","article-title":"Lung cancer statistics","volume":"893","author":"Torre","year":"2016","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.cllc.2020.05.014_bib4","doi-asserted-by":"crossref","first-page":"e0121323","DOI":"10.1371\/journal.pone.0121323","article-title":"Lung cancer incidence trends by gender, race and histology in the United States, 1973-2010","volume":"10","author":"Meza","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.cllc.2020.05.014_bib5","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.lungcan.2014.01.009","article-title":"International trends in lung cancer incidence by histological subtype: adenocarcinoma stabilizing in men but still increasing in women","volume":"84","author":"Lortet-Tieulent","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2020.05.014_bib6","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1200\/JCO.2005.04.177","article-title":"Clinical model to predict survival in chemonaive patients with advanced non\u2013small-cell lung cancer treated with third-generation chemotherapy regimens based on Eastern Cooperative Oncology Group data","volume":"23","author":"Hoang","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2020.05.014_bib7","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1093\/annonc\/mdq067","article-title":"The influence of sex and histology on outcomes in non\u2013small-cell lung cancer: a pooled analysis of five randomized trials","volume":"21","author":"Wheatley-Price","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2020.05.014_bib8","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1097\/JTO.0000000000000678","article-title":"The International Association for the Study of Lung Cancer Lung Cancer Staging Project: proposals for the revision of the N descriptors in the forthcoming 8th Edition of the TNM Classification for Lung Cancer","volume":"10","author":"Asamura","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2020.05.014_bib9","doi-asserted-by":"crossref","first-page":"437","DOI":"10.2147\/CMAR.S63603","article-title":"A\u00a0comprehensive review of nongenetic prognostic and predictive factors influencing the heterogeneity of outcomes in advanced non\u2013small-cell lung cancer","volume":"6","author":"Cuyun Carter","year":"2014","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.cllc.2020.05.014_bib10","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1097\/JTO.0000000000000673","article-title":"The IASLC Lung Cancer Staging Project: proposals for the revision of the M descriptors in the forthcoming eighth edition of the TNM Classification of Lung Cancer","volume":"10","author":"Eberhardt","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2020.05.014_bib11","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","article-title":"The IASLC Lung Cancer Staging Project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM Classification for Lung Cancer","volume":"11","author":"Goldstraw","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2020.05.014_bib12","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1097\/JTO.0b013e318221f701","volume":"6","author":"Russell","year":"2011","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2020.05.014_bib13","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1200\/JCO.2014.58.8335","article-title":"Subtype classification of lung adenocarcinoma predicts benefit from adjuvant chemotherapy in patients undergoing complete resection","volume":"33","author":"Tsao","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2020.05.014_bib14","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1097\/JTO.0000000000000490","article-title":"Prognostic impact and clinicopathological correlations of the cribriform pattern in pulmonary adenocarcinoma","volume":"10","author":"Warth","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2020.05.014_bib15","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1001\/jama.2014.3741","article-title":"Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs","volume":"311","author":"Kris","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.cllc.2020.05.014_bib16","doi-asserted-by":"crossref","first-page":"6531","DOI":"10.1074\/jbc.270.12.6531","article-title":"Lung cell\u2013specific expression of the murine surfactant protein A (SP-A) gene is mediated by interactions between the SP-A promoter and thyroid transcription factor-1","volume":"270","author":"Bruno","year":"1995","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.cllc.2020.05.014_bib17","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1097\/00000478-200009000-00004","article-title":"Value of thyroid transcription factor-1 immunostaining in distinguishing small cell lung carcinomas from other small cell carcinomas","volume":"24","author":"Ordonez","year":"2000","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.cllc.2020.05.014_bib18","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1097\/00000478-200206000-00010","article-title":"TTF-1 expression in pulmonary adenocarcinomas","volume":"26","author":"Yatabe","year":"2002","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.cllc.2020.05.014_bib19","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1101\/gad.10.1.60","article-title":"The T\/ebp null mouse: thyroid-specific enhancer-binding protein is essential for the organogenesis of the thyroid, lung, ventral forebrain, and pituitary","volume":"10","author":"Kimura","year":"1996","journal-title":"Genes Dev"},{"key":"10.1016\/j.cllc.2020.05.014_bib20","doi-asserted-by":"crossref","first-page":"24992","DOI":"10.1074\/jbc.R113.491647","article-title":"The complexity of thyroid transcription factor 1 with both pro- and anti-oncogenic activities","volume":"288","author":"Mu","year":"2013","journal-title":"J\u00a0Biol Chem"},{"issue":"pt B","key":"10.1016\/j.cllc.2020.05.014_bib21","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.cca.2015.01.023","article-title":"Prognostic value of TTF-1 expression in patients with non\u2013small cell lung cancer: a meta-analysis","volume":"451","author":"Qian","year":"2015","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.cllc.2020.05.014_bib22","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.lungcan.2017.03.015","article-title":"Prognostic impact of TTF-1 expression in patients with stage IV lung adenocarcinomas","volume":"108","author":"Schilsky","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2020.05.014_bib23","doi-asserted-by":"crossref","first-page":"e95479","DOI":"10.1371\/journal.pone.0095479","article-title":"The relationship between TTF-1 expression and EGFR mutations in lung adenocarcinomas","volume":"9","author":"Shanzhi","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.cllc.2020.05.014_bib24","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1200\/JCO.2007.15.0375","article-title":"Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non\u2013small-cell lung cancer","volume":"26","author":"Scagliotti","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2020.05.014_bib25","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1200\/JCO.2012.47.1102","article-title":"PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non\u2013small-cell lung cancer","volume":"31","author":"Paz-Ares","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2020.05.014_bib26","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1023\/A:1020363010465","article-title":"Using propensity scores to help design observational studies: application to the tobacco litigation","volume":"2","author":"Rubin","year":"2001","journal-title":"Health Serv Outcomes Res Method"},{"key":"10.1016\/j.cllc.2020.05.014_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1214\/09-STS313","article-title":"Matching methods for causal inference: a review and a look forward","volume":"25","author":"Stuart","year":"2010","journal-title":"Stat Sci"},{"key":"10.1016\/j.cllc.2020.05.014_bib28","series-title":"Statistical Power Analysis for the Behavioral Sciences","first-page":"24","volume":"20-1","author":"Cohen","year":"1988"},{"key":"10.1016\/j.cllc.2020.05.014_bib29","first-page":"1471","article-title":"Efficacy of pemetrexed plus platinum doublet chemotherapy as first-line treatment for advanced nonsquamous non\u2013small-cell-lung cancer: a systematic review and meta-analysis","volume":"9","author":"Xiao","year":"2016","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.cllc.2020.05.014_bib30","doi-asserted-by":"crossref","DOI":"10.1177\/1010428317691186","article-title":"Thyroid transcription factor 1 expression is associated with outcome of patients with non-squamous non\u2013small cell lung cancer treated with pemetrexed-based chemotherapy","volume":"39","author":"Fiala","year":"2017","journal-title":"Tumour Biol"},{"key":"10.1016\/j.cllc.2020.05.014_bib31","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1097\/JTO.0b013e3182208ea8","article-title":"Significance of thymidylate synthase and thyroid transcription factor 1 expression in patients with nonsquamous non\u2013small cell lung cancer treated with pemetrexed-based chemotherapy","volume":"6","author":"Sun","year":"2011","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2020.05.014_bib32","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1097\/JTO.0b013e3182a406a3","article-title":"Associations between TS, TTF-1, FR-alpha, FPGS, and overall survival in patients with advanced non\u2013small-cell lung cancer receiving pemetrexed plus carboplatin or gemcitabine plus carboplatin as first-line chemotherapy","volume":"8","author":"Gr\u00f8nberg","year":"2013","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2020.05.014_bib33","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/JTO.0b013e318206a221","article-title":"International Association for the Study of Lung Cancer\/american thoracic society\/european respiratory society international multidisciplinary classification of lung adenocarcinoma","volume":"6","author":"Travis","year":"2011","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2020.05.014_bib34","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1038\/modpathol.2012.76","article-title":"Ciliated adenocarcinomas of the lung: a tumor of non-terminal respiratory unit origin","volume":"25","author":"Park","year":"2012","journal-title":"Mod Pathol"},{"key":"10.1016\/j.cllc.2020.05.014_bib35","doi-asserted-by":"crossref","first-page":"5489","DOI":"10.21873\/anticanres.12882","article-title":"TTF-1 expression predicts the merit of additional antiangiogenic treatment in non-squamous non\u2013small cell lung cancer","volume":"38","author":"Takeuchi","year":"2018","journal-title":"Anticancer Res"},{"key":"10.1016\/j.cllc.2020.05.014_bib36","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1200\/JCO.2004.11.022","article-title":"Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non\u2013small-cell lung cancer","volume":"22","author":"Johnson","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2020.05.014_bib37","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.lungcan.2017.05.021","article-title":"Treatment outcomes by histology in REVEL: a randomized phase III trial of ramucirumab plus docetaxel for advanced non\u2013small cell lung cancer","volume":"112","author":"Paz-Ares","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2020.05.014_bib38","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1016\/j.ejca.2015.08.008","article-title":"Single organ metastatic disease and local disease status, prognostic factors for overall survival in stage IV non\u2013small cell lung cancer: results from a population-based study","volume":"51","author":"Hendriks","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.cllc.2020.05.014_bib39","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1097\/JTO.0000000000000630","article-title":"The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification","volume":"10","author":"Travis","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2020.05.014_bib40","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1093\/ejcts\/ezv316","article-title":"International Association for the Study of Lung Cancer\/American Thoracic Society\/European Respiratory Society classification predicts occult lymph node metastasis in clinically mediastinal node-negative lung adenocarcinoma","volume":"49","author":"Yeh","year":"2016","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.cllc.2020.05.014_bib41","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1200\/JCO.2013.50.1049","article-title":"Predictive value of the International Association for the Study of Lung Cancer\/American Thoracic Society\/European Respiratory Society classification of lung adenocarcinoma in tumor recurrence and patient survival","volume":"32","author":"Hung","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2020.05.014_bib42","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.4103\/0973-1482.197535","article-title":"Diagnostic value of core biopsy histology and cytology sampling of mediastinal lymph nodes using 21-gauge EBUS-TBNA needle","volume":"12","author":"Vaidya","year":"2016","journal-title":"J\u00a0Cancer Res Ther"},{"key":"10.1016\/j.cllc.2020.05.014_bib43","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1136\/thoraxjnl-2014-206677","article-title":"Diagnostic procedures for non\u2013small-cell lung cancer (NSCLC): recommendations of the European Expert Group","volume":"71","author":"Dietel","year":"2016","journal-title":"Thorax"},{"key":"10.1016\/j.cllc.2020.05.014_bib44","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jtho.2018.12.005","article-title":"Best practices recommendations for diagnostic immunohistochemistry in lung cancer","volume":"14","author":"Yatabe","year":"2019","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2020.05.014_bib45","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/PAI.0000000000000082","article-title":"Dakin Hach\u00e9 KA. CytoLyt\u00ae fixation and decalcification pretreatments alter antigenicity in normal tissues compared with standard formalin fixation","volume":"23","author":"Gruchy","year":"2015","journal-title":"Appl Immunohistochem Mol Morphol"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730420301546?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730420301546?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:10:19Z","timestamp":1761505819000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730420301546"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":45,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S1525730420301546"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2020.05.014","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pemetrexed-Based Chemotherapy Is Inferior to\u00a0Pemetrexed-Free Regimens in Thyroid Transcription Factor 1 (TTF-1)-Negative, EGFR\/ALK-Negative Lung Adenocarcinoma: A Propensity Score Matched Pairs Analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2020.05.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}